Look at the chart. Every uptick there is a high-volume short sale to try to drive down the price. This won't last very long, but is interesting to watch. Shorts are desperate!
They are continuing to develop their business base and enroll patients on an ever widening scale.
No. The number built into the price is $13.07M with EPS at -$0.50/share. Anything beyond that is not baked in yet.
It will be interesting to see how much EU revenue comes in this quarter.
We are only scratching the surface of the value now that revenues continue to roll in.
The longer away the buyout is, the more $$$ we will make. It is a 10-bagger from here before the buyout.
Good call, but your price per share is a little light.
Elaborate. What do you mean an expansion of indications? Do you mean off label use? Do you mean an expansion of revenue targets? Number of patients? Number of countries?